Biomedical subjects

M D Blanco

Publications and source records attributed to M D Blanco.

23 records · Page 2Linked to original sources

PubMed1994

Influence of degree of crosslinking on 5-fluorouracil release from poly(2-hydroxyethyl methacrylate) hydrogels.

Controlled release of 5-fluorouracil (5-FU) from poly(2-hydroxyethyl methacrylate) (PHEMA) hydrogels with three different degrees of crosslinking is reported. The swelling kinetic of PHEMA hydrogels in water was studied at different disc thicknesses and temperatures, and the diffusion coefficient and activation energy of the process were obtained. The gels were loaded with 5-FU by immersing them in concentrated aqueous solutions of the drug. The 5-FU release was studied as a function of temperature, disc thickness, disc load and degree of crosslinking of the gels; the diffusion coefficient and activation energy of the release process were also obtained.

Chemistry, Pharmaceutical↗

PubMed1994

Anticancer drug, ara-C, release from pHEMA hydrogels.

This study investigates the controlled release of cytarabine (ara-C), an anticancer drug, from a polymeric matrix of lightly cross-linked poly(2-hydroxyethyl methacrylate) (pHEMA). The swelling of pHEMA discs in water was analysed as a function of temperature and thickness of xerogel discs. The fractional swelling was linear in (time)1/2 for short time periods. Drug release kinetics were examined as a function of temperature, initial drug load and thickness of pHEMA discs. The fraction of available drug release was also linear in (time)1/2 during the initial stages. These studies allow for the determination of diffusion coefficients for both the transport of water into the hydrogel and ara-C release from the polymer.

Biocompatible Materials↗

PubMed1987

[Interactions of lysozyme with Pb(II) using viscosimetry and dilatometry of the equilibrium of dialysis].

The conformational hen white egg lysozyme in the binary mixture water/Pb2+ as a function of the binary mixture composition has been studied. Intrinsic viscosity, partial specific volume and preferential adsorption parameter in the 0-0.100 M Pb2+ concentration range has been experimentally measured. The obtained results suggest that the observed conformational transition is a consequence of the interactions established between lysozyme and Pb2+ cation.

Adsorption↗

PubMedDate not supplied

Slow releasing of ara-C from poly(2-hydroxyethyl methacrylate) and poly(2-hydroxyethyl methacrylate-co-N-vinyl-2-pyrrolidone) hydrogels implanted subcutaneously in the back of rats.

The release of cytarabine (ara-C) from poly(2-hydroxyethyl methacrylate) and poly(2-hydroxyethyl methacrylate-co-N-vinyl-2pyrrolidone) hydrogels cross-linked with different amounts of ethyleneglycol dimethacrylate (EGDMA) 'in vivo' has been studied. Two ara-C loaded hydrogel discs, each with 25 mg of the drug, were subcutaneously implanted in the back of male Wistar rats. Total ara-C dose was 230 mg kg(-1). Ara-C and ara-U plasmatic concentration were determined by HPLC. Periods of constant drug concentration are observed from all gels. Ara-C concentrations in the steady-state are between 19.0 +/- 2.0 and 2.2 +/- 0.8 micromol l(-1). The release time of ara-C was between 3 days from pH EMA 0.5% and 16 days from H80/VP20/E15 gels. These results are very different of that obtained when ara-C is administered by intraperitoneal injection, in this case peaks of maximum concentration (between 24 +/- 1 and 3.9 +/- 0.4 microg ml(-1)) 30 min after the injection are originated, and no drug is detected 4 h after the injection.

Animals↗

PubMedDate not supplied

In vitro controlled release of bupivacaine from albumin microspheres and a co-matrix formed by microspheres in a poly(lactide-co-glycolide) film.

Albumin microspheres cross-linked with glutaraldehyde and loaded with bupivacaine, a local anaesthetic, were synthesized (138 +/- 59 microm diameter). A matrix formed by bupivacaine-loaded microspheres in a poly(lactide-co-glycolide) film was prepared in order to improve the controlled release of the drug. In vitro release of the drug was determined in phosphate buffer at 37 degrees C in the absence and in the presence of protease type VIII to mimic a biological system. The effect of temperature and protease on bupivacaine as a function of time was examined; both of them cause a degradative effect on the drug. A rapid release (60 +/- 8% of the drug) takes place at 1 h, and maximum release is found at 50 +/- 6 h from microspheres with swelling. In the presence of protease, maximum release of bupivacaine from microspheres is found at 28 +/- 2 h; the microspheres disappear at 8 days. Inclusion of bupivacaine-loaded microspheres in a poly(lactide-co-glycolide) film causes a slower release of the drug, up to 18 days, with swelling. In the presence of protease, the polymer protects bupivacaine-loaded microspheres from degradation, which takes place at 20 days.

Animals↗